Sector: Life Sciences

Latest content

Novartis’ Gilenya woes deepen as Dusseldorf court overturns preliminary injunction

Despite unusual circumstances of the fingolimod disputes, the cases highlight some of the potential pitfalls facing pharma patentees in Germany and elsewhere in Europe

14 August 2023

Navigating China’s patent linkage system: challenges and opportunities

Its evolution and the related implications are critical for both originators and generics

09 August 2023

UPC lawsuits dominated by Europe-based corporations and SMEs

The new court is being used far more by local companies than by innovators from other parts of the world

07 August 2023

Bristol-Myers’ $560 million settlement is yet another success for its patent licensing campaign

AstraZeneca is the third Big Pharma company to pay BMS a nine-figure sum for the use of its immuno-oncology patents

04 August 2023

Delaware landmark preliminary injunction dismissal is bad news for biologics patentees

Rare decision in a BPCIA dispute gives a tactical advantage to biosimilar producers

01 August 2023

Mylan off the hook for $50 million tax bill for patent expenses

US appellate court confirms IRS may no longer deny generic drugmakers the ability to deduct ANDA litigation costs

31 July 2023

$7 billion Roivant deal would be ultimate vindication of its pioneering IP commercialisation model

The company’s distinctive dealmaking approach has produced many successes to date

28 July 2023

Bringing IP strategy lessons to a pioneering pharma company

Head of IP Nick Finnie speaks to IAM about the importance of visibility when working for a smaller company competing in a global market

21 July 2023

Genentech sues Biogen as new wave of biosimilars disputes grows

Case concerns 20 asserted patents but this figure may be whittled down during litigation process

21 July 2023

CRISPR patent interference overturned by Federal Circuit

SNIPR Biome has five patents revived but more disputes are on the horizon

18 July 2023

Unlock unlimited access to all IAM content